The path forward for T cell engagers in patients with prostate cancer.
Publication/Presentation Date
2-24-2026
Abstract
T cell engagers (TCEs) recruit T cells to the tumor microenvironment (TME) to induce antitumor immune responses. TCEs have demonstrated promising clinical responses in patients with metastatic castration-resistant prostate cancer and have advanced into phase 3 clinical trials. Here we provide an overview of the mechanisms of action of TCEs, including both CD3-targeted and CD28-targeted agents, and review the clinical development of these agents for prostate cancer. We propose a path forward for TCEs in prostate cancer, in which innovative clinical trials will facilitate a biological understanding of mechanisms of efficacy and toxicity to inform: (1) development of predictive biomarkers for patient selection; (2) rational combination strategies; and (3) targeted treatments for toxicity management, ultimately delivering broad clinical benefit for patients with lethal prostate cancer.
Volume
14
Issue
2
ISSN
2051-1426
Published In/Presented At
Subudhi, S. K., Siddiqui, B. A., Zarrabi, K. K., Kelly, W. K., & Drake, C. G. (2026). The path forward for T cell engagers in patients with prostate cancer. Journal for immunotherapy of cancer, 14(2), e013905. https://doi.org/10.1136/jitc-2025-013905
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
41734994
Department(s)
Administration and Leadership
Document Type
Article